In addition to brain imaging, patients underwent cognitive tests to assess memory, executive function, and psychomotor speed.
Clinicians must keep this potentially increased risk in mind when prescribing long-term use of a specific anticholinergic drug to patients with DM suffering from OAB.
The researchers found that higher baseline HOMA-IR and fasting insulin levels were independent predictors of poorer verbal fluency performance.
The increased risk of stroke was only observed among patients with diabetes controlled by insulin.
Women who were pregnant and slept for less than 6 hours per night or had poor sleep quality had a greater risk of developing gestational diabetes.
The study supports previous findings of hyperarousal of the inflammatory system as a mechanism of insulin resistance.
Patients with type 2 diabetes and major depressive disorder spent a significant amount of time experiencing depressive episodes.
Ghrelin was a significant predictor for executive function impairment in patients with T2DM.
The findings are relevant for patients with insulin resistance but no history of diabetes.
All but one type of statin was associated with a dose-dependent neurprotective benefit against Parkinson's.
Differences in brain volume have previously been found in adults with Type 2 diabetes.
Selective serotonin reuptake inhibitor use increases risk for patients hospitalized with stroke.
Sleep deprivation does not worsen impairment in type 1 diabetes, but prolongs recovery.
Long-term intervention was associated with lower white matter hyperintensity volume.
The risk of epilepsy is nearly 3 times greater in patients with Type 1 diabetes.
Type 2 diabetes appears to be more common in adolescents with autism spectrum disorders.
The drugs have an anti-inflammatory effect in patients with both MS and metabolic syndrome.
After 6 months, the CPAP group saw a greater decrease in HbA1c levels compared to controls.
Patients taking pioglitazone saw a 24% reduction in risk for recurrent stroke or myocardial infarction compared to placebo.
People with type 2 diabetes have approximately a 60% greater risk of dementia those those without.
Poorly controlled HbA1c levels were associated with a 50% greater risk of dementia later in life.
Those with diabetes had higher concentrations of total tau in CSF, as well as thinner cortical thickness regardless of dementia diagnosis.
Higher HOMA-IR score was linked to poorer language skills in women.
Hippocampal-specific insulin resistance in a rat model was shown to downregulate insulin receptor expression.
Those with type 1 diabetes were 61% more likely to develop dementia after adjustments.
Reduced risk was only seen in patients actively taking glitazones.
Addressing neuropathy early on in prediabetes is essential to successful symptom management.
Those with more complications from diabetes had a higher risk of developing dementia.
Scores on a learning and memory test decreased an average of 12% in people with diabetes.
Having all three health conditions was linked to 15 years of reduced life expectancy.
Neurology Advisor Articles
- Vitamin D Deficiency Affects Cognition in Multiple Sclerosis
- Hypothalamus May Play a Central Role in Chronic Migraine
- An Interdisciplinary Approach to Advanced Parkinson's Care
- Migraine Attacks Associated With Reduced Dopamine Levels
- Polypharmacy in Schizophrenia May Have Adverse Effect on Cognition
- Alzheimer's Mortality Increasing, But So Is At-Home Care
- Special Diets, Supplements for Autism Not Backed by Solid Evidence
- In MS, Disease Duration, Lesion Load Predict Relapses and Disability Progression
- Ocrelizumab May Improve Cognitive Function in Relapsing Multiple Sclerosis
- Teriflunomide for MS Associated With Low Rates of Infection, Lymphopenia